| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Exelixis Inc (NASDAQ: EXEL)
EXEL Technical Analysis
3
| As on 9th Jun 2023 EXEL SHARE Price closed @ 19.20 and we RECOMMEND Buy for LONG-TERM with Stoploss of 19.20 & Buy for SHORT-TERM with Stoploss of 18.88 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EXELSHARE Price
| Open | 19.30 | Change | Price | % |
| High | 19.43 | 1 Day | -0.15 | -0.78 |
| Low | 19.18 | 1 Week | -0.08 | -0.41 |
| Close | 19.20 | 1 Month | 1.03 | 5.67 |
| Volume | 4554475 | 1 Year | 0.27 | 1.43 |
| 52 Week High 23.16 | 52 Week Low 14.96 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| EXEL Daily Charts |
EXEL Intraday Charts |
Whats New @ Bazaartrend |
EXEL Free Analysis |
|
|
EXEL Important Levels Intraday
| RESISTANCE | 19.68 |
| RESISTANCE | 19.53 |
| RESISTANCE | 19.43 |
| RESISTANCE | 19.34 |
| SUPPORT | 19.06 |
| SUPPORT | 18.97 |
| SUPPORT | 18.87 |
| SUPPORT | 18.72 |
EXEL Forecast April 2024
| 4th UP Forecast | 24.35 |
| 3rd UP Forecast | 22.7 |
| 2nd UP Forecast | 21.68 |
| 1st UP Forecast | 20.66 |
| 1st DOWN Forecast | 17.74 |
| 2nd DOWN Forecast | 16.72 |
| 3rd DOWN Forecast | 15.7 |
| 4th DOWN Forecast | 14.05 |
EXEL Weekly Forecast
| 4th UP Forecast | 21.63 |
| 3rd UP Forecast | 20.85 |
| 2nd UP Forecast | 20.37 |
| 1st UP Forecast | 19.89 |
| 1st DOWN Forecast | 18.51 |
| 2nd DOWN Forecast | 18.03 |
| 3rd DOWN Forecast | 17.55 |
| 4th DOWN Forecast | 16.77 |
EXEL Forecast2024
| 4th UP Forecast | 35.64 |
| 3rd UP Forecast | 30.37 |
| 2nd UP Forecast | 27.11 |
| 1st UP Forecast | 23.85 |
| 1st DOWN Forecast | 14.55 |
| 2nd DOWN Forecast | 11.29 |
| 3rd DOWN Forecast | 8.03 |
| 4th DOWN Forecast | 2.76 |
Exelixis Inc ( NASDAQ USA Symbol : EXEL )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EXEL Business Profile
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California. Address: 1851 Harbor Bay Parkway, Alameda, CA, United States, 94502
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service